Other and unspecified disorders of globe

H7_GLOBENAS

eye disease: A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma. [NCIt:C26767]

Suggest a new description

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — H44.8, H44.9 Hospital discharge: ICD-9 — 360[8-9] Cause of death: ICD-10 — H44.8, H44.9 Cause of death: ICD-9 — 360[8-9] 2 out of 7 registries used, show all original rules.	68
4. Check minimum number of events None	68
5. Include endpoints None	68
6. Filter based on genotype QC (FinnGen only)	68

Control definitions (FinnGen only)

Control exclude: H7_VITREOUS

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2

NAME	H7_GLOBENAS
CONTROL_EXCLUDE	H7_VITREOUS
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	H44[8-9]
HD_ICD_9	360[8-9]
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	H44[8-9]
COD_ICD_9	360[8-9]
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Other and unspecified disorders of globe based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	657	254	394
Only index persons	443	195	248
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.01
Only index persons	0.01	0.01	0.01
Median age at first event (years)
Whole population	63.29	62.09	63.90
Only index persons	54.96	56.97	53.37

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	68	33	35
Unadjusted period prevalence (%)	0.01	0.01	0.02
Median age at first event (years)	61.13	56.97	65.05

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
61: Matched controls
612

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

H44.8

ICD-10 Finland

Other disorders of globe

+∞

32.1

H44.9

ICD-10 Finland

Disorder of globe, unspecified

+∞

21.0

3608A

ICD-9 Finland

Disorders of the globe, Other disorders of globe[ANOPHTALMIA ARTEFACTA]

+∞

16.4

Z90.0

ICD-10 Finland

Acquired absence of part of head and neck

+∞

8.5

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3003458) Phosphate [Moles/volume] in Serum or Plasma

3.32

3.94

6.3

7.7

1.1

mmol/l

0.21

(3023024) Carbon dioxide [Partial pressure] in Capillary blood

4.52

3.85

5.9

2.2

5.5

5.0

kpa

—

(42870588) Differential panel, method unspecified - Blood

151

2.61

3.52

6.8

4.8

—

(40758558) Short blood count panel - Blood

121

2.52

3.05

11.5

8.8

—

(3012095) Magnesium [Moles/volume] in Serum or Plasma

2.73

2.86

4.1

4.2

0.8

mmol/l

0.17

(3005772) Bilirubin.conjugated [Moles/volume] in Serum or Plasma

3.04

2.81

1.8

3.0

4.1

9.6

umol/l

—

(3022313) Gas panel - Capillary blood

5.07

2.67

5.9

1.5

—

(3004490) Bicarbonate [Moles/volume] standard in Capillary blood

5.36

2.46

7.3

1.8

23.9

24.6

mmol/l

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

2.45

2.05

1.6

1.4

—

(3007853) Bacteria identified in Skin by Aerobe culture

2.44

1.92

2.8

1.4

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

2.24

1.89

1.9

1.6

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

196

1.95

1.88

1.9

112.2

95.8

pmol/l

1.99

(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection

4.40

1.85

1.0

1.3

—

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

4.06

1.74

1.4

2.3

—

(3015235) Bicarbonate [Moles/volume] in Capillary blood

4.06

1.74

2.6

25.8

26.7

mmol/l

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

2.31

1.73

1.8

1.6

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

183

1.90

1.73

4.3

3.2

—

(3045414) Leukocytes [Presence] in Urine

3.51

1.55

2.8

1.7

—

(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma

219

1.76

1.44

11.0

8.3

1.2

mmol/l

0.08

194

(3000620) Complement C3 [Mass/volume] in Serum or Plasma

2.91

1.31

1.6

1.3

1.2

1.1

g/l

—

(3011960) Natriuretic peptide B [Mass/volume] in Serum or Plasma

2.31

1.26

3.1

1.8

109.1

111.2

ng/l

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

2.34

0.96

1.7

1.4

—

(4035726)

2.02

0.92

2.0

1.2

—

(36304419) Bacteria [Presence] in Urine

134

1.58

0.83

3.8

2.8

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

108

1.63

0.83

3.8

2.3

—

(3027945) Reticulocytes/100 erythrocytes in Blood

1.80

0.79

2.4

3.3

1.8

1.7

—

(3000330) Specific gravity of Urine by Test strip

2.26

0.78

4.4

5.0

—

(3042936) Bacteria identified in Isolate by Culture

1.67

0.75

2.9

3.1

—

(3002256) Pathology report gross observation

1.75

0.73

1.3

—

(3023368) Bacteria identified in Blood by Culture

140

1.50

0.68

7.1

4.3

—

(3022621) pH of Urine by Test strip

1.66

0.67

3.4

2.3

—

(43534045) MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal

1.78

0.65

1.0

—

(3012544) pH of Venous blood

1.58

0.61

8.3

4.3

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

1.55

0.53

2.5

1.4

—

(3037467) Urinalysis macro (dipstick) panel - Urine

351

1.34

0.50

5.7

4.3

—

(3000991) Gas panel - Venous blood

1.58

0.50

16.4

8.8

—

(40771025) 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma

198

1.33

0.45

2.6

2.4

74.0

77.1

nmol/l

0.27

171

(3007220) Creatine kinase [Enzymatic activity/volume] in Serum or Plasma

152

1.35

0.43

2.8

2.1

157.7

273.8

u/l

0.47

147

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

1.61

0.43

1.4

1.5

—

(3016293) Bicarbonate [Moles/volume] in Serum or Plasma

1.55

0.42

4.6

4.7

28.8

25.4

mmol/l

—

(40768804) Tissue Pathology biopsy report

219

1.30

0.42

3.3

2.0

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

1.46

0.40

2.0

1.6

—

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

493

1.34

0.39

25.8

14.9

22.6

22.7

mg/l

0.01

382

(3012516) Albumin [Mass/volume] in Urine

136

1.33

0.38

4.1

2.9

50.2

64.5

mg/l

0.23

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

270

1.27

0.38

3.4

2.8

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

225

1.25

0.33

4.7

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

122

1.29

0.30

3.9

3.7

—

(3032080) INR in Blood by Coagulation assay

208

1.24

0.29

9.0

7.0

1.3

1.2

inr

—

(40760892) CBC W Ordered Manual Differential panel - Blood

1.30

0.27

10.8

7.7

—

(3022217) INR in Platelet poor plasma by Coagulation assay

1.25

0.26

17.3

23.6

—

1.3

—

(3031040) Bacteria [#/volume] in Urine by Automated count

339

1.20

0.26

6.1

4.2

—

74.5

—

(3026008) Bacteria identified in Urine by Culture

164

1.22

0.24

4.5

3.0

—

(3017732) Neutrophils [#/volume] in Blood

1.30

0.23

5.2

3.8

5.0

3.4

e9/l

—

(3048816) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood

1.24

0.22

2.0

4.5

1.2

mmol/l

—

(3041096) Erythrocytes [Presence] in Urine by Automated

146

1.22

0.22

4.2

3.7

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

1.21

0.22

1.0

2.1

—

(3033705) Calcium.ionized [Moles/volume] in Venous blood

0.00

0.21

0.0

2.5

—

(3010156) C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method

0.00

0.21

0.0

1.6

—

1.5

—

(3017895) Helicobacter pylori Ab [Units/volume] in Serum

0.00

0.21

0.0

1.3

—

(3000475) Leukocytes [#/volume] in Synovial fluid

0.00

0.21

0.0

1.5

—

5404.0

—

(3012110) Lysozyme [Mass/volume] in Serum or Plasma

0.00

0.21

0.0

1.6

—

9.0

—

(40758310) Human epididymis protein 4 [Moles/volume] in Serum or Plasma

0.00

0.21

0.0

1.1

—

917.0

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

132

0.80

0.20

5.0

4.4

28.0

23.2

—

(3044640) Blood type and Crossmatch panel - Blood

149

1.19

0.18

4.3

2.3

—

(3009542) Hematocrit [Volume Fraction] of Blood

439

1.15

0.15

24.5

15.9

37.8

39.5

0.44

304

(40761535) Cells panel - Urine sediment

1.12

0.10

2.8

3.0

—

(40761511) CBC panel - Blood by Automated count

516

1.12

0.09

21.0

13.2

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

0.82

0.08

1.8

1.6

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

1.05

0.08

1.4

1.6

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

1.03

0.08

1.6

1.9

—

(3003694) ABO and Rh group [Type] in Blood

112

1.09

0.03

1.2

1.3

—

(3044889) 12 lead EKG panel

342

1.05

0.02

3.7

3.8

—

(3013512) EKG study

146

0.95

0.00

5.9

4.0

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

206

0.96

0.00

5.2

4.1

—

(3015736) pH of Urine

205

0.97

0.00

3.7

3.8

—

(3019900) Cholesterol [Moles/volume] in Serum or Plasma

485

0.96

0.00

4.4

4.5

4.6

mmol/l

0.35

437

(1761868) Lipid panel - Serum or Plasma

155

0.96

0.00

2.2

2.9

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

1.02

0.00

2.6

1.6

—

(3010380) Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid

0.00

0.0

1.0

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

0.0

4.1

—

112.0

—

(3050238) Crystals [Presence] in Synovial fluid by Light microscopy

0.00

0.0

1.3

—

(3015635) Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma

0.00

0.0

1.3

—

(3019230) Fractional oxyhemoglobin in Venous blood

0.00

0.0

1.6

—

62.3

—

(3044290) Cell count panel - Cerebral spinal fluid

0.00

0.0

1.0

—

(3021952) Alkaline phosphatase isoenzymes [Enzymatic activity/volume] in Serum or Plasma by Heat stability

0.00

0.0

1.5

—

(1002102) Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma

0.00

0.0

1.2

—

(43055089) Myosin Ab [Presence] in Serum or Plasma by Immunoblot

0.00

0.0

1.2

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

1.00

0.00

1.9

1.3

—

(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture

0.00

0.0

1.5

—

(3044941) Cell count panel - Synovial fluid

0.00

0.0

1.3

—

(42870365) C reactive protein [Mass/volume] in Blood by High sensitivity method

0.00

0.0

1.3

—

(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma

0.00

0.0

1.7

—

(1175715) Chlamydophila pneumoniae IgM Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.1

—

(4094501)

0.00

0.0

1.4

—

(3032773) Endomysium IgG Ab [Titer] in Serum

0.00

0.0

1.0

—

(3011166) Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid

0.00

0.0

1.0

—

(3047007) Chlamydophila sp Ab [Presence] in Serum

0.00

0.0

1.1

—

(3017918) Cytomegalovirus IgG Ab [Titer] in Serum or Plasma

0.00

0.0

1.3

—

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

4.4

—

16.7

—

(40766189) Gliadin peptide IgG Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.0

—

(43055361) Metamyelocytes/Leukocytes [Pure number fraction] in Blood by Manual count

0.00

0.0

3.4

—

(3000494) Fungus identified in Specimen by Culture

0.95

0.00

1.0

1.8

—

(40768800) Prostate Pathology biopsy report

0.00

0.0

1.2

—

(3014973) Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid

0.00

0.0

1.0

—

(3006257) Acetylcholine receptor Ab [Moles/volume] in Serum

0.00

0.0

1.3

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

0.00

0.0

1.3

—

(3007844) Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.2

—

(3011648) Oxygen content in Venous blood

0.00

-0.00

0.0

1.0

—

11.2

—

(3022756) Ceruloplasmin [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

255.6

—

(3011288) Drugs identified in Urine by Screen method

0.00

-0.00

0.0

2.2

—

(3005136) Cladosporium herbarum IgE Ab [Units/volume] in Serum

0.00

-0.00

0.0

1.0

—

(4281824)

0.00

-0.00

0.0

1.2

—

(21492711) Cytomegalovirus IgG Ab avidity [Presence] in Serum or Plasma by Immunoassay

0.00

-0.00

0.0

1.4

—

(3019601) Blood group antibody investigation [Interpretation] in Plasma or RBC

0.00

-0.00

0.0

1.4

—

(4024509)

0.00

-0.00

0.0

1.0

—

(3003740) Influenza virus B Ag [Presence] in Specimen

0.00

-0.00

0.0

1.2

—

(3022803) Oxygen [Partial pressure] adjusted to patient's actual temperature in Arterial blood

0.00

-0.00

0.0

3.4

—

(3045156) Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Arterial blood

0.00

-0.00

0.0

3.4

—

(3005715) Vancomycin [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

13.4

—

11.9

—

(4027681)

0.00

-0.00

0.0

1.0

—

(3023511) Choriogonadotropin [Units/volume] in Urine

0.00

-0.00

0.0

2.0

—

(3045788) Cell count panel - Pleural fluid

0.00

-0.00

0.0

1.2

—

(3002523) Influenza virus A Ag [Presence] in Specimen

0.00

-0.00

0.0

1.2

—

(3013201) Beta-2-Microglobulin [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

2.2

—

4.0

—

(3005570) Glucose [Moles/volume] in Urine

0.00

-0.00

0.0

1.6

—

(40759883) Oligoclonal Bands IgG [Presence] in Cerebral spinal fluid by Isoelectric focusing

0.00

-0.00

0.0

1.0

—

(3000855) Microscopic observation [Identifier] in Vaginal fluid by Gram stain

0.00

-0.00

0.0

1.6

—

Mortality – FinRegistry

↥

Association

Association between endpoint H7_GLOBENAS and mortality.

Females

No data

Males

Parameter	HR [95% CI]	p-value
H7_GLOBENAS	1.845 [1.24, 2.76]	0.003
Birth year	0.986 [0.98, 1.0]	0.005

During the follow-up period (1.1.1998 — 31.12.2019), 71 out of 175 males with H7_GLOBENAS died.

Mortality risk

Mortality risk for people of age

years, who have H7_GLOBENAS.

N-year risk	Females	Males
1	No data	0.327%
5	No data	1.96%
10	No data	5.069%
15	No data	9.458%
20	No data	15.972%

Relationships between endpoints

↥

Index endpoint: H7_GLOBENAS – Other and unspecified disorders of globe

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Other and unspecified disorders of globe

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

Matched cohort

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints